Multiple Myeloma

Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

The FDA granted orphan drug designation to SAR446523 for relapsed/refractory multiple myeloma.

Panelists discuss how post-chimeric antigen receptor (CAR) T follow-up care involves coordinated joint visits between academic centers and community oncologists for the first 3 months, with ongoing education about delayed toxicities such as cranial nerve palsies, parkinsonism, and immune effector cell enterocolitis

Panelists discuss how early referral for chimeric antigen receptor (CAR) T-cell therapy is crucial for accessing clinical trials and achieving optimal outcomes, with comprehensive patient education covering unique adverse effects such as cytokine release syndrome (CRS), neurologic toxicities, and secondary malignancies balanced against extraordinary efficacy data.

Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Krzysztof Jamroziak, PhD, discusses findings from the phase 2 PREDATOR-MRD trial (NCT03697655).

Panelists discuss how the 5-year follow-up data from CARTITUDE-1 shows 33% of patients remain alive and progression-free at 5 years with sustained minimal residual disease (MRD) negativity, suggesting the potential for functional cure in multiple myeloma, with lower disease burden at infusion being a key predictor of long-term remission

Panelists discuss how the CARTITUDE-4 subgroup analysis demonstrated that cilta-cel provides significant progression-free and overall survival advantages over standard of care across all patient subgroups, including those with high-risk cytogenetics, extramedullary disease, and varying numbers of prior therapy lines.

Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.

Prerna Mewawalla, MD, explains the roles of cilta-cel and ide-cel in clinical practice for the treatment of relapsed/refractory multiple myeloma.

The European Commission and Health Canada have approved belantamab mafodotin-based combinations for relapsed/refractory multiple myeloma.

Subcutaneous daratumumab received EU approval for the treatment of patients with smoldering multiple myeloma at high risk of developing multiple myeloma.

Darren Pan, MD, outlines late-onset toxicities related to CAR T-cell therapies in multiple myeloma and their management.

Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy is increasingly being used earlier in the treatment paradigm rather than in the late-stage, with better disease control prior to infusion leading to improved outcomes and reduced toxicity, particularly for high-risk patients or those with functional high-risk disease relapsing sooner than expected.

Panelists discuss how approximately 75% to 80% of patients with multiple myeloma are eligible for chimeric antigen receptor (CAR) T-cell therapy at some point during their care, with eligibility determined by safety criteria including organ function and comorbidities, logistical feasibility, and efficacy considerations rather than direct comparisons to autologous transplant.

Darren Pan, MD, highlighted key sequencing strategies for T-cell redirection therapy in relapsed/refractory multiple myeloma.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.